FOR IMMEDIATE RELEASE

Molecular Targeting Technologies, Inc. and Temple University Announced Patent approval for Anti-thrombotic Agents

West Chester, PA, September 22, 2021—Molecular Targeting Technologies, Inc. (MTTI) and Temple University announce the issuance of U.S. patent "Anti-thrombotic Agents and Methods of Use Thereof" (US11,090,309).

Anticoagulants break up and prevent blood clots, stopping vessel blockage, limiting adverse effects of heart attack and stroke. They can also prevent blood clotting during and post-surgery and may help lower long-term risk of thrombotic (clotting) events. This patent describes the use of liposomes, particularly, X-DPA-22, as an anti-thrombotic agent for acute clinical and prophylactic applications.

"Our anti-thrombotic agent has real clinical value. Existing anticoagulants like heparin and warfarin can cause low platelet counts and bleeding (thrombocytopenia). Our novel molecule showed acute anti-thrombotic activity in preclinical models without thrombocytopenia," said Parkson Chong, PhD, Professor of Medical Genetics and Molecular Biochemistry, Professor in the Center for Substance Abuse Research and Professor of Biomedical Education and Data Science at the Lewis Katz School of Medicine at Temple University.

Dr. Brian Gray, SVP of Product Development at MTTI said "X-DPA-22 was custom designed to bind to lipid membranes and target the disease biomarker, phosphatidylserine. We've found multiple clinical applications for this construct."

Dr. Lawrence Goldfinger, Associate Professor in the Cardeza Foundation for Hematologic Research, Department of Medicine, Thomas Jefferson University, commented, "X-DPA-22 may also prevent platelet-induced clotting during vascular surgery, reduce post-surgical complications and be useful in controlling disseminated intravascular coagulation and thrombo-inflammatory complications in multiple clinical settings."

Dr. Chris Pak, President & CEO of Molecular Targeting Technologies, Inc. commented, "Cardiac patients need a potent, less problematic anti-thrombotic agent. We are committed to clinical translation of X-DPA-22 for them."

Molecular Targeting Technologies, Inc. is a privately held, well financed, clinical stage biotech, developing targeted radiotherapeutics and diagnostics for rare cancers. MTTI has received an exclusive worldwide license from the National Institutes of Health to commercialize selected targeted radiopharmaceuticals covered by their Evans blue (EB) platform technology patents. MTTI is committed to building value by acquiring and

translating innovative imaging, radiopharmaceutical and theranostic assets to improve human health, reduce healthcare costs and reward stakeholders. MTTI expects to orchestrate multiple clinical trials in 2021-22. More information: www.mtarget.com

Contact: Chris Pak, Email: cpak@mtarget.com; Tel: (610) 738-7938.